Polycystic Kidney Disease (PKD)- Market Insights, Epidemiology and Market Forecast- 2027

DelveInsight Business Research LLP

Albany, NY -- (SBWIRE) -- 12/28/2018 -- DelveInsight has announced the addition of the "Polycystic Kidney Disease (PKD)- Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

Report provides an overview of the disease and market size of Polycystic Kidney Disease (PKD) for the seven major markets i.e., the United States, EU5 (France, Germany, Italy, Spain, the UK) and Japan. The Report also covers the overview, treatment practices and Polycystic Kidney Disease (PKD) forecasted epidemiology from 2018 to 2027, segmented by seven major markets.

Request for sample pages

Polycystic Kidney Disease (PKD) is a genetic disorder which results in the uncontrolled growth of cysts in the kidney eventually leading to kidney failure, or end-stage renal disease (ESRD). Cysts may also develop in other organs, particularly the liver and can range from just a few to many with varying size from a pinhead to as large as a grapefruit. Mainly Mutations in the PKD1, PKD2, and PKHD1 genes cause polycystic kidney disease. There are two types of PKD- autosomal dominant (ADPKD) and autosomal recessive (ARPKD). Autosomal dominant PKD causes cysts only in the kidneys and often called "adult PKD" as it is mostly present between 30 and 50 years old. Autosomal recessive PKD causes cysts to grow in both the kidneys and the liver and often called "infantile PKD" because it occurs in babies in their first few months of life, or even before they are born. Men and Women effected equally as often.

Mutations in either the PKD1 or PKD2 gene can cause ADPKD whereas Mutations in the PKHD1 gene cause ARPKD. PKD1 and PKD2 encode polycystin 1 and polycystin 2 and approximately 1 in 1,000 people bear a mutation in either PKD1 or PKD2 genes worldwide. A small percentage of cases are not caused by gene mutations are called as acquired polycystic kidney disease, which is not classified as PKD. The ADPKD is the more common type and affects more than 600,000 Americans and 12.4 million people worldwide. About 9 out of every 10 people with PKD have the autosomal dominant form. The prevalence of ADPKD is estimated to range from 1 in 500 to 1,000 people. ARPKD is a rare form which is inherited to children, when both parents carry the mutations in the PKHD1 gene. The estimated prevalence range of 1 in 20,000 to 40,000 children worldwide and it happens in only 1 out of every 10 cases of ADPKD.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies

1. Sanofi
2. Palladio Biosciences
3. Regulus Therapeutics
4. XORTX Therapeutics
And many others

Drugs covered

1. Venglustat
2. Lixivaptan
3. RGLS4326
4. XRx-008
And many others

Report Scope

The report covers a descriptive overview of the Polycystic Kidney Disease (PKD) explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Polycystic Kidney Disease (PKD) disease and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Polycystic Kidney Disease (PKD), are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Polycystic Kidney Disease (PKD) market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Polycystic Kidney Disease (PKD) market

For more information on this press release visit: http://www.sbwire.com/press-releases/polycystic-kidney-disease-pkd-market-insights-epidemiology-market-1113190.htm